Funding for this research was provided by:
pharmaceutical research and manufacturers of america foundation
u.s. department of defense (W81XWH-18-0401)
national institute on aging (R01AG052608)
national cancer institute (F31CA257349)
national institute of general medical sciences (GM124922)
american diabetes association pathway to stop diabetes accelerator award (1-18-ACE-15)
Received: 9 March 2021
Accepted: 17 August 2021
First Online: 1 September 2021
: The collection of PBMC1 and PBMC2 samples and data from human subjects used in this research has been approved by UConn Health IRB and conducted in accordance with the principles expressed in the Declaration of Helsinki. Written informed consent for participation in the study including the collection, use, and sharing of data was obtained from participants under UConn IRB approved protocol (16-071J-1/George Kuchel). The research involving the use of commercially obtained unidentifiable human specimens from (a) cadaveric pancreatic islets from Prodo Laboratories and NIH Integrated Islet Distribution Program and (b) pooled commercially available unidentifiable PBMCs from HemaCare does not meet the definition of human subjects research under applicable Federal Regulations 45 CFR 46.
: Not applicable. The manuscript does not include any identifiable details, images, or videos of the participants. No personal identifiers have been included in this manuscript nor will be shared. All data shared in this manuscript are deidentified.
: The authors declare that they have no competing interests.